An 11‐year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre

Fosbury, Emma; Szychot, Elwira; Slater, Olga; Mathias, Mary; Sibson, Keith

doi:10.1002/pbc.26246

Cited by 13 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The laboratory findings are characterised by prolonged APTT, low factor VIII, and low von Willebrand factor (VWF) antigen and activity. The use of VWF concentrate is recommended for surgical procedures or bleeding, but the response may be variable until the underlying tumour is reduced (Fosbury et al , ).…”

Section: Management Of Thrombocytopenia and Coagulopathymentioning

confidence: 99%

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

et al. 2018

View full text Add to dashboard Cite

Section: Management Of Thrombocytopenia and Coagulopathymentioning

confidence: 99%

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

et al. 2018

View full text Add to dashboard Cite

“…Methylation inactivation of enriched tumor suppressor genes such as ADCY4 [145], FBLN1 [146], FBN2 [147], ADAMTS9 [148], NELL2 [149] and PCDH18 [150] were important for progression of various cancers such as breast cancer, colorectal cancer, nasopharyngeal cancer and kidney cancer, but loss of these genes may be linked with development of WT. Enriched genes such as VWF (Von Willebrand factor) [151] and ACVR2B [152] were identi ed with progression of WT. ITPR1 was linked with activation of autophagy in kidney cancer [153], but this gene may be responsible for induction of autophagy in WT.…”

Section: Discussionmentioning

confidence: 99%

Hub Genes and Key Pathway Identification in Wilms Tumor Based on Bioinformatics Analysis

Vastrad¹,

Vastrad²,

Kotturshetti³

2020

Preprint

View full text Add to dashboard Cite

Wilms tumor (WT) is a childhood kidney cancer with unknown etiology. Gene expression analysis has become very essential in WT. Thus, we performed an integrated analysis of gene expression data to identify new molecular mechanisms and key functional genes in WT. Gene expression (GSE60850) dataset was downloaded from Gene Expression Omnibus. Differentially expressed genes (DEGs) were identified using limma. Pathway and Gene Ontology (GO) enrichment analyses were performed for the DEGs by ToppGene database. Then, protein–protein interaction (PPI) networks and modules were established by the Mentha database and PEWCC1, and visualized by Cytoscape software. Target gene - miRNA regulatory network and target gene - TF regulatory network were established by the Network Analyst database and visualized by Cytoscape software. Finally, survival analysis, expression analysis, stage analysis, mutation analysis, immunohistochemical (IHC) analysis, receiver operating characteristic (ROC), reverse transcription polymerase chain reaction (RT-PCR) and immune infiltration analysis of hub genes was performed. We identified 988 DEGs ultimately including 502 up regulated genes and 486 down regulated genes. Pathway and GO enrichment analysis revealed that DEGs were mainly enriched in D-myo-inositol (3,4,5,6)-tetrakisphosphate biosynthesis, platelet activation, cholesterol biosynthesis III, and complement, coagulation cascades, embryo development, cell surface, DNA-binding transcription factor activity, carboxylic acid metabolic process, extracellular space and signaling receptor binding. FN1, AURKA, TRIM41, NFKBIA, TXNDC5, SIN3A, MAGI1, GPRASP2, UCHL1 and FXYD6 were filtrated as the hub genes. These identified DEGs and hub genes facilitate our knowledge of the underlying molecular mechanism of WT and have the potential to be used as diagnostic and prognostic biomarkers or therapeutic targets for WT.

show abstract

“…One of the more common pediatric malignancies associated with AvWS is Wilms' tumor [12]. A retrospective evaluation of the coagulation profile of 190 children with Wilms' tumor revealed AvWS in eight for an incidence of approximately 4% [13].…”

Section: Discussionmentioning

confidence: 99%

Acquired von Willebrand Disease in a Child With Wilms’ Tumor: Implications for Postoperative Regional Anesthesia

Kedir¹,

Tumin²,

Veneziano³

et al. 2018

J Med Cases

View full text Add to dashboard Cite

Regional anesthetic techniques including epidural anesthesia are a safe and effective method of providing postoperative analgesia while avoiding the potential adverse physiologic effects of systemic opioids. However, clinical scenarios or co-morbid conditions such as abnormal coagulation function may preclude the use of neuraxial analgesia. We present a 2-year-old boy who presented for nephrectomy due to Wilms' tumor disease. Preoperative evaluation of coagulation function revealed an elevated partial thromboplastin related to acquired von Willebrand disease and therefore a wound catheter was used instead of epidural analgesia. Coagulation function guidelines for epidural anesthesia are reviewed and alternative techniques such as a wound catheter are discussed.

show abstract

An 11‐year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre

Cited by 13 publications

References 18 publications

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Hub Genes and Key Pathway Identification in Wilms Tumor Based on Bioinformatics Analysis

Acquired von Willebrand Disease in a Child With Wilms’ Tumor: Implications for Postoperative Regional Anesthesia

Contact Info

Product

Resources

About